Retatrutide TRIUMPH-4 Phase 3 Data: 28.7% Body Weight Reduction

TRIUMPH-4 (NCT05931367) is the pivotal Phase 3 trial of retatrutide (LY3437943), a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, developed by Eli Lilly. Topline data reported in the first quarter of 2026 showed a mean body weight reduction of 28.7 percent from baseline at week 88 in the highest dose arm, compared with 2.1 percent in the placebo arm, in adults with obesity without type 2 diabetes.

This is the largest mean body weight reduction reported to date in a Phase 3 obesity trial with a pharmacologic intervention. It exceeds the weight loss reported for tirzepatide in SURMOUNT-1 (22.5 percent at 72 weeks), for semaglutide 2.4 mg in STEP 1 (14.9 percent at 68 weeks), and approaches efficacy ranges previously associated only with bariatric surgery.

Retatrutide is a 39 amino acid synthetic peptide engineered to activate three incretin and related receptors with balanced potency. The GLP-1 and GIP components provide glucose-dependent insulin secretion, slowing of gastric emptying, and central nervous system effects on satiety and food reward. The glucagon receptor component adds a distinct thermogenic and hepatic lipolytic effect that is hypothesized to drive the additional weight loss beyond the dual GLP-1/GIP agonist tirzepatide.

Glucagon receptor activation increases hepatic fatty acid oxidation, reduces hepatic lipogenesis, and raises basal energy expenditure. The inclusion of glucagon agonism in retatrutide requires careful balancing against its glucose-raising effect, which is offset in retatrutide by the glucose-lowering GLP-1 and GIP activities, resulting in net glucose homeostasis that is either neutral or favorable across studied populations.

TRIUMPH-4 is a 88 week randomized, double-blind, placebo-controlled Phase 3 trial enrolling approximately 2,100 adults with a body mass index of 30 kg per square meter or greater, or 27 kg per square meter with at least one weight-related comorbidity, without type 2 diabetes. Participants were randomized 1:1:1:1 to retatrutide 4 mg, 8 mg, 12 mg once weekly, or matching placebo, each in combination with lifestyle intervention.

Dose escalation occurred over the first 20 weeks with 2 mg monthly increments. The primary endpoints were percentage change in body weight from baseline to week 88 and the proportion of participants achieving at least 5 percent body weight reduction. Key secondary endpoints included changes in waist circumference, blood pressure, HbA1c, lipid profile, and body composition as measured by DXA in a subset.

Mean body weight reductions from baseline at week 88 were 18.9 percent in the 4 mg arm, 24.2 percent in the 8 mg arm, and 28.7 percent in the 12 mg arm, compared with 2.1 percent in the placebo arm. A total of 91 percent of participants on the 12 mg dose achieved at least 5 percent weight reduction, 83 percent achieved at least 10 percent, 70 percent achieved at least 15 percent, 55 percent achieved at least 20 percent, and 33 percent achieved at least 25 percent weight reduction.

Weight loss continued throughout the 88 week treatment period without clear evidence of a plateau in the pooled population, a pattern observed previously in retatrutide Phase 2 data and which distinguishes it from the typical plateau seen with dual GLP-1/GIP and single GLP-1 agonists around weeks 52 to 68.

Secondary endpoints showed favorable changes consistent with the weight loss magnitude. Systolic blood pressure decreased by an estimated 10 to 12 mmHg in the 12 mg arm, waist circumference decreased by approximately 20 cm, and triglycerides decreased by approximately 35 percent. HbA1c in participants with prediabetes decreased by a mean of 0.6 percent, with 68 percent returning to normoglycemia.

Magnetic resonance imaging substudies showed reductions in visceral adipose tissue volume exceeding 40 percent and reductions in hepatic steatosis measured by proton density fat fraction exceeding 60 percent. These hepatic effects are consistent with the glucagon receptor component of retatrutide action.

Mechanistic subanalyses and indirect calorimetry substudies from the retatrutide Phase 2 program indicated that basal metabolic rate measured at steady state was modestly preserved or increased during retatrutide treatment, contrasting with the expected decrease in metabolic rate during caloric restriction and significant weight loss. This finding supports the hypothesis that glucagon receptor agonism counteracts adaptive thermogenesis during weight loss.

The inclusion of glucagon agonism is the primary differentiator between retatrutide and tirzepatide. Whether the additional efficacy comes from direct glucagon-mediated energy expenditure, hepatic fat oxidation, appetite regulation, or a combination is an active area of translational research.

The adverse event profile of retatrutide in TRIUMPH-4 was consistent with the incretin class. Gastrointestinal adverse events predominated: nausea (38 percent at 12 mg), diarrhea (29 percent), vomiting (21 percent), and constipation (18 percent). Most events were mild to moderate and occurred during dose escalation. Adverse event-related discontinuation rates were 11 percent in the 12 mg arm versus 4 percent on placebo.

Glucagon receptor-related effects were modest. Small mean increases in resting heart rate (4 to 6 beats per minute) and transient elevations in hepatic aminotransferases were observed in a minority of participants, typically normalizing over the course of treatment. No meaningful hyperglycemia signal was detected, and glycemic outcomes were favorable across dose arms.

Cross-trial efficacy rankings for mean body weight reduction in obesity populations without diabetes, as currently published, are approximately: retatrutide 12 mg at 28.7 percent over 88 weeks, tirzepatide 15 mg at 22.5 percent over 72 weeks (SURMOUNT-1), CagriSema at approximately 20 percent over 68 weeks (REDEFINE 1), survodutide at approximately 19 percent at 46 weeks (Phase 2), semaglutide 2.4 mg at 14.9 percent over 68 weeks (STEP 1), and oral semaglutide 25 mg at 13.6 percent over 64 weeks (OASIS 4).

Direct head-to-head trials across these molecules are limited. Cross-trial comparisons are informative for understanding the landscape but are not sufficient for clinical decision-making due to differences in trial populations, endpoints, and run-in periods.

Based on publicly communicated Eli Lilly timelines, the company plans to submit a New Drug Application for retatrutide to the U.S. Food and Drug Administration in the second half of 2026, with a potential approval decision in the second half of 2027. Supporting data will include the full TRIUMPH-4 obesity dataset alongside TRIUMPH-3 (type 2 diabetes), TRIUMPH-HCM (heart failure with preserved ejection fraction), and ongoing trials in metabolic dysfunction-associated steatohepatitis and osteoarthritis.

If approved on this timeline, retatrutide would become the first marketed triple agonist and would reset the efficacy ceiling for pharmacologic weight management. Commercial manufacturing of the peptide at the volumes required will represent a significant scale challenge given the existing GLP-1 class supply constraints.